

# Redefining long-term outcomes in newly diagnosed advanced ovarian cancer

## Expert perspectives on integrating personalised medicine

Sunday, 19<sup>th</sup> September 2021; 08:45–10:15 CEST

Channel 6

### Faculty



**Chair**  
**Nicoletta Colombo**  
European Institute of Oncology  
Milano, Italy



**Ana Oaknin**  
Vall d'Hebron Institute of Oncology  
Barcelona, Spain



**Christian Marth**  
Innsbruck Medical University  
Innsbruck, Austria



**David O'Malley**  
The Ohio State University  
Ohio, USA

### Agenda

**Key considerations for treatment of newly diagnosed advanced ovarian cancer**

Nicoletta Colombo

**Implementing Personalised Medicine:** Evidence review and patient case-based discussions:

**HRD positive:** BRCA mutation

Ana Oaknin

**HRD positive:** No BRCA mutation, high genomic instability score

Christian Marth

**HRD negative:** Low genomic instability score

David O'Malley

**Future perspectives**

Nicoletta Colombo

**Live panel discussion and Q&A**

19<sup>th</sup> September 2021 | 09:50–10:15 CEST

AstraZeneca 

This industry symposium is organised and sponsored by AstraZeneca; it is a non-promotional, peer-to-peer scientific exchange meeting intended for healthcare professionals to discuss and debate on the current evidence of BRCAm and HRD in ovarian cancer and its implications in clinical practice. This symposium may contain information regarding investigational products and investigational uses which are not yet approved in the EU